Table 5.
Patients undergoing HSCT
| Patient | Age at HSCT (months) | Time from diagnosis to HSCT (months) | Conditioning regimen | Donor type | Source of stem cells | GVHD prophylaxis | AGVHD | CGVHD |
|---|---|---|---|---|---|---|---|---|
| 1 | 36 | 33 | Treo/Flu/Thio/ATG | Haploidentical Donor | PB | CsA | N | N |
| 2 | ||||||||
| 1*st HSCT | 65 | 5 | Flu/Treo/Alem | Matched UD | PB | CsA/MMF | N | N |
| 2*nd HSCT | 72 | 12 | Flu/Bu/ATG | Matched UD | PB | CsA/Mtx | N | N |
| 3 | 17 | 5 | Flu/Bu/ATG | Mismatched FD | BM | CsA/Mtx | N | N |
| 4 | 12 | 6 | Flu/Treo | Matched FD | BM | CsA/Mtx | N | N |
| 5 | 7 | 3 | Treo/Flu/Thio/ATG | Haploidentical Donor | PB | CsA/Cyc | N | N |
Treo, Treosulfan; Flu, Fludarabine; Thio, Thiotepa; Alem, Alemtuzumab; Bu, Busulfan; ATG, Anti-thymocyte globulin; CsA, Cyclosporine; Cyc, Cyclophosphamide; MMF, Mycophenolate; Mtx, Methotrexate; FD, Family Donor; UD, Unrelated Donor; PB, Peripheral Blood; BM, Bone Marrow; AGVHD, Acute GVHD; CGVHD, Chronic GVHD.